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Abstract
Pharmacogenomics is yet to fulfill its promise of manifestly altering clinical medicine. As one 
example, a predictive test for tardive dyskinesia (an adverse drug reaction consequent to 
antipsychotic exposure) could greatly improve the clinical treatment of schizophrenia but human 
studies are equivocal. A complementary approach is the mouse-then-human design in which a 
valid mouse model is used to identify susceptibility loci which are subsequently tested in human 
samples. We used inbred mouse strains from the Mouse Phenome Project to estimate the 
heritability of haloperidol-induced activity and orofacial phenotypes. 159 mice from 27 inbred 
strains were chronically treated with haloperidol (3 mg/kg/day via subdermal slow-release pellets) 
and monitored for the development of vacuous chewing movements (VCMs, the mouse analog of 
TD) and other movement phenotypes derived from open field activity and the inclined screen test. 
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The test battery was assessed at 0, 30, 60, 90, and 120 days in relation to haloperidol exposure. As 
expected, haloperidol caused marked changes in VCMs, activity in the open field, and EPS. 
Unexpectedly, factor analysis demonstrated that these measures were imprecise assessments of a 
latent construct rather than discrete constructs. The heritability of a composite phenotype was ~0.9 
after incorporation of the longitudinal nature of the design. Murine VCMs are a face valid animal 
model of antipsychotic-induced TD and heritability estimates from this study support the 
feasibility of mapping of susceptibility loci for VCMs.
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INTRODUCTION
The truth of the proposition that pharmacogenomics is crucial to the future of medicine is 
usually assumed 1. The logic seems sound: humans vary in propensity for adverse drug 
reactions and efficacy, and genetic testing could deliver a cardinal feature of individualized 
medicine via tailoring pharmacotherapy to individual genomes. However, given limited 
progress with human pharmacogenomic studies, we believe it timely to explore a 
complementary paradigm 1, mouse-then-human designs. In the first stage, we expose mouse 
strains to humanlike steady-state drug concentrations under rigorous experimental 
conditions and carefully and reliably measured outcomes of interest. Control is achieved for 
genetic background as well as for extraneous environmental effects. These phenotypic data 
also allow estimation of heritability. As all of these mice have been genotyped using a 
modern GWAS chip 2, future work will entail genetic mapping as in silico analyses. In the 
second stage, the human orthologs of genomic regions implicated in mouse are studied in 
human samples to determine whether the association replicates across species. In this way, 
the mouse is used to screen the genomic search space in order to identify a small number of 
candidate regions with high prior probabilities that are then tested in humans. Most of the 
multiple comparison debt is paid in mouse, and precious human samples are used only for 
regions that are far more probable than average.
In this report, we investigate a mouse model of human tardive dyskinesia (TD). TD is a 
clinically important adverse drug reaction whose basis is unknown. Exposure to 
conventional or typical antipsychotics (prototype haloperidol) causes extrapyramidal 
syndromes (EPS). Acute EPS occurs in ~40% of subjects and includes akathisia, acute 
dystonia, and secondary parkinsonism 3. TD is a late-onset form of EPS that develops in 
~35% of subjects treated chronically with typical antipsychotics 4 and may be irreversible in 
about half of subjects 5. TD is characterized by repetitive, involuntary, and purposeless 
movements primarily of the orofacial region (e.g., chewing and tongue protrusion) 6. There 
are no heritability estimates for TD. Despite the lack of these crucial data, multiple human 
candidate gene association studies have been published 7–12. This literature has not 
converged on strong and replicated associations.
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After chronic treatment with typical antipsychotics, rodents show purposeless mouth 
openings in the vertical plane, or vacuous chewing movements (VCMs) 13. VCMs are a 
phenotypically and pharmacologically valid animal model of TD that has been used for 
decades by behavioral pharmacologists 13. The full argument for the validity of VCMs as a 
rodent model for TD is summarized in Table S1. In Figure S1, we add a new component to 
this argument. TD can persist in humans for years after exposure to a typical antipsychotic; 
chronic haloperidol exposure in mouse induces VCMs that persist for 1.5 years (a large 
fraction of the mouse lifespan) and well after haloperidol levels are undetectable.
The purpose of this paper is to initiate evaluation-of-concept studies whose overarching goal 
is to investigate whether the MTH design can be used to inform studies of human TD. We 
show that it is possible to deliver human-like steady state concentrations of haloperidol. As 
expected, VCMs develop reliably and we show that VCMs can be measured reliably. We 
then exposed 27 genetically diverse inbred mouse strains to standardized doses of 




All testing procedures were conducted in strict compliance with the “Guide for the Care and 
Use of Laboratory Animals” (Institute of Laboratory Animal Resources, National Research 
Council, 1996) and approved by the Institutional Animal Care and Use Committee of the 
University of North Carolina.
Animals
Male mice (aged 8–10 weeks) from 27 inbred strains were obtained from the Jackson 
Laboratory (Bar Harbor, ME) as part of the Mouse Phenome Project. The 22 classical-
derived strains were 129S1/SvImJ, A/J, AKR/J, BALB/cByJ, BTBR T<+> tf/J, C3H/HeJ, 
C57BL/6J, C57BLKS/J, CBA/J, DBA/2J, DDY, FVB/NJ, KK/HIJ, MA/MY, MRL/MpJ, 
NOD/LtJ, NON/SHILTJ, NZL, NZO, NZW/LacJ, SJL/J, and SM/J. The five wild-derived 
strains were CAST/EiJ, MOLF/EiJ, MSM/Ms, PWK, and WSB/EiJ.
Male mice were studied to minimize variation due to sex. Animals were maintained on a 
12h light:12h dark schedule with lights on at 0700. The housing room was maintained at 20–
24°C with 40–50% relative humidity. Mice were housed in standard 20 cm × 30 cm 
ventilated polycarbonate cages with laboratory grade Bed-O-Cob bedding. Water and Purina 
ProLab IsoPro 3000 were available ad libitum. A small section of PVC pipe was present in 
each cage for enrichment. In pilot work, we observed considerable weight loss due to 
dehydration in the first few days after exposure to haloperidol. This appeared to be due to 
acute EPS resulting in an inability to rear and to reach water and chow on the roof of the 
cage. Thus, for the first few days after exposure to haloperidol, food and water were 
positioned near the bedding surface. All mice from each strain were group-housed 
(maximum of five mice per cage) except that BALB/cByJ, CAST/EiJ, and SJL/J mice were 
separated due to fighting after 7, 10 and 13 weeks of housing.
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The goal was to achieve a human-like steady-state concentration of haloperidol (10–50 
nanomoles/L, nM, or 3.75–19 ng/ml) 14 for a minimum of 30 days. Pilot studies showed 
that implantable pellets yielded considerably lower coefficients of variation in steady-state 
haloperidol concentrations in comparison to injections, implantable mini-pumps, or 
haloperidol in drinking water (Supplemental Methods, Table S2). Dose-ranging pilot studies 
in C57BL/6J mice indicated that 3.0 mg/kg/day (60 day release tablets) yielded plasma 
haloperidol concentrations in the 10–50 nM range. Haloperidol pellets (Innovative Research 
of America; Sarasota, FL) 15 were implanted subcutaneously with a trocar under two 
minutes of isoflurane anesthesia (pilot studies indicated that anesthesia minimized handling 
stress and pain). Pellets of incremental dosages were implanted to compensate for varying 
body weights. Mice were followed for 120 days in total in order to examine changes in 
VCMs when haloperidol concentrations waned. Blood plasma was collected via tail nick for 
drug concentration assays after 30, 60, 90 and 120 days of exposure to haloperidol. 
Haloperidol assays were performed using mass spectrometry by the Analytical 
Psychopharmacology Laboratory at the Nathan Kline Institute for Psychiatric Research 
(Orangeburg, NY).
Scoring VCMs
High-resolution digital videotapes of orofacial behavior were made by modifying the 
method of Tomiyama et al. 16. Each mouse was briefly anesthetized using isoflurane and 
placed in a restrictor device (a plastic collar that lightly restrained the mouse around the 
neck) attached to a horizontal platform (Figure S2A). Collars were composed of two 
semicircular elements: a lower trough fixed to the platform and an upper restrainer that 
completed light enclosure of the neck. Both the diameter of the collar and its height above 
the platform were adjustable according to body size in order to allow a comfortable posture 
to be maintained. This restrictor device allowed a high-resolution digital camcorder (JVC 
Everio GZ-MG360BU; Wayne, NJ) to be focused onto the orofacial region from below with 
minimal disturbance to facial movements. Each mouse was placed in the restrictor device 
for 25 minutes, and the final 15 minutes were scored for orofacial movement phenotypes: 
tongue protrusions, overt chewing movements, subtle chewing movements and jaw tremors. 
Tongue protrusions and chewing movements were measured as counts of individual events 
and tremors as total duration (seconds). A chewing movement was defined as a single mouth 
opening in the vertical plane not directed toward physical material, not occurring during a 
period of struggling, and not coincident with tongue protrusion. Overt chewing movements 
were distinguished from subtle chewing movements if the interior of the oral cavity could be 
seen. Each video recording was randomly assigned to one of three raters and scored using 
the Observer video analysis system (Noldus, The Netherlands). Crucially, raters were 
blinded to all study data including strain and study time point. Inter-rater reliability among 
the three raters was high (intra-class correlation of 0.92), as determined by individual 
scoring of 32 randomly-assigned and blinded video recordings. All raters were initially 
trained by an experienced rater in a three-step process: viewing of a training tape with clips 
from several different strains of mice demonstrating each movement phenotype; 
comparative scoring of a training set composed of 36 video clips (one haloperidol and one 
placebo treated mouse from 18 different strains); and scoring of training tapes continued 
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until the new rater reached consensus criterion. To monitor drift, the same training tape was 
periodically and blindly scored. Orofacial observations were made on days 0, 30, 60, 90 and 
120 relative to drug treatment (day 1).
Open field activity
Extrapyramidal side effects may appear as general motor deficits in mice, therefore 
spontaneous locomotor activity in the open field 17 was measured for 1 hour using a 
photocell-equipped automated open field apparatus (Versamax system, Accuscan 
Instruments, Columbus, OH; 40 cm wide × 40 cm long × 30 cm high). Four phenotypes 
were extracted from these activity data: total distance traveled (cm), vertical activity 
(number of beam breaks), stereotypy (repeated breaking of the same beam; number of beam 
breaks), and time spent in the central region of the chamber (percent of total time; central 20 
cm × 20 cm). Activity chambers were inside sound-attenuating boxes equipped with 
houselights and fans. Open field activity was measured on days 0, 30, 60, 90 and 120 
relative to drug treatment (day 1).
Extrapyramidal side effects (EPS)
The inclined screen test 18 (Figure S1B) was used as an index of Parkinsonian rigidity and 
sedation. Mice were placed on a wire mesh screen inclined at 45° and the latency to move 
all four paws was recorded (to a maximum of 300 seconds). EPS was measured on days 0, 
30, 60, 90 and 120 relative to drug treatment (day 1).
Statistical Analyses
Linear mixed effects models were used to decompose phenotype variances for the 
calculation of heritability and inter-rater reliability as well as to assess the significance of 
covariate fixed effects (R 2.6.0 and Stata 9.2). Mixed models are generally considered 
superior to competing analytical approaches for variance decomposition of longitudinal data 
because they can accommodate missing observations and irregular assessment spacing, and 
enable modeling of random effects and within-subject residual covariance structures 19.
Heritability was calculated using intra-class correlation coefficients. First, we present 
heritability estimates for the raw data as a baseline to which the processed data can be 
compared. Second, heritability estimates for change scores were estimated (i.e., √timet – 
√time0). Given that many phenotypes had non-zero values prior to exposure, change scores 
isolate the phenotypic component attributable to haloperidol exposure. Third, a major 
weakness of the two prior methods of estimating heritability is inefficiency. Longitudinal 
analyses are appropriate to our study design and incorporate all available data to refine the 
heritability measures by studying over-time response trajectories induced by haloperidol for 
each mouse (as opposed to data from time points in isolation). The heritabilities of the over-
time trajectories in haloperidol-induced movement disorder phenotypes were assessed using 
an extension of the mixed model for behavioral genetic analysis (see Figure S3 for idealized 
method illustration) 20. For each phenotype, the optimal functional form of the over-time 
trajectory was determined by fitting a series of mixed models in which the trajectory was 
specified as a linear trend, a plateau (linear change until timet, and flat thereafter), or a lag 
effect (no phenotype change until timet, and flat thereafter), with models fit for all possible 
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plateau/lag points. After determining optimal trajectory functional forms by comparing 
model fit statistics, three level mixed models (assessments nested within individual mice 
nested within strains) were fit that decomposed trajectory variance into components due to 
mouse-specific and strain-specific differences. Trajectory heritabilities were calculated as 
the ratio of strain-level variance to strain-level + mouse-level variance. Fourth, there are 
strong intercorrelations between the nine dependent variables (Table S4). If each observed 
phenotype is considered as an imperfect measurement of an unobserved latent factor, it may 
be possible to discover unexpected connections across phenotypes and to derive improved 
estimates of more fundamental traits. Thus, we applied factor analysis to examine the factor 
structure of the mouse-specific response trajectories (i.e., the random slope coefficients) 
(MPlus 5.21) 21–23. Orthogonal iterative principal factor exploratory models were fit 
followed by an examination of various rotations. The variance of the latent trajectory factors 
underlying the individual response phenotype trajectories was decomposed into strain- and 
mouse-level components, and heritabilities of the latent trajectory factors were calculated as 
the ratio of strain-level variance to strain-level + mouse-level variance.
RESULTS
Mice & haloperidol delivery
Haloperidol tablets were initially implanted in 156 mice from 27 inbred strains with the goal 
of obtaining a human-like steady-state concentration of haloperidol (10–50 nM) for a 
minimum of 30 days. A pilot dose-ranging study suggested that this could be achieved using 
3.0 mg/kg/day for a 60-day tablet (Figure S1). Four of five MOLF/EiJ mice died within one 
day of haloperidol exposure and all five mice were excluded (mortality was likely due to 
temperature dysregulation or dehydration due to acute EPS). Subsequently, five MOLF/EiJ 
mice were successfully run through the protocol when the implanted haloperidol dose was 
split over successive days. In addition, all four BTBR mice developed a dermatological 
problem, which may be related to characteristic coat abnormalities in this strain, two months 
after drug treatment and were sacrificed. Eight additional BTBR mice were subsequently run 
through the unmodified protocol successfully. Thus, the sample for this report consists of 
159 mice from 27 strains. Complete data for the key dependent variables (VCMs) were 
available for three time-points (0, 30, and 60 days) for 157 mice (98.7%) and for five time-
points (0, 30, 60, 90, and 120 days) for 148 mice (93.1%).
Table S3 summarizes the number of mice used in this experiment, attrition over time, and 
the numbers of mice that achieved the minimum desired haloperidol concentrations at each 
time-point. The numbers of mice with steady-state plasma haloperidol concentrations ≥10 
nM were 156/159 at 30 days, 151/158 at 60 days, 73/149 at 90 days, and 9/148 at 120 days, 
consistent with the function of the 60 day release tablets. Haloperidol concentrations in the 
three mice under the 10 nM threshold at 30 days were 9.4, 9.6, and 9.9 nM. Figure 1 shows 
full data for plasma haloperidol concentrations at 30, 60, 90, and 120 days. Although there is 
considerable variation across strains, haloperidol levels were almost always tightly clustered 
within each strain-time point with the possible exception of the heaviest strain (the mean 
baseline weight for NZL mice was four times the lightest strain). The medians (inter-quartile 
ranges) of the coefficients of variation for haloperidol concentrations across strains were 
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0.19 (0.15–0.25) at 30 days and 0.19 (0.13–0.25) at 60 days. These data are consistent with 
the pilot data in Table S2 and indicate that the delivery method almost always achieved our 
goal of exposure to sustained human-like haloperidol steady-state concentrations.
We investigated the impact of confounding variables on the substantial strain variation in 
haloperidol concentrations (Supplemental Methods). Linear regression modeling was used 
to investigate the effects of mouse strain, pellet dosage, and body weight on plasma 
haloperidol concentration at 30 days. Mouse strain was the predominant effect (P ~ 10−16). 
The heritability of log10(haloperidol) was 0.70 at 30 days and 0.67 at 60 days during the 
period when drug was being released by the pellets (heritabilities were lesser as haloperidol 
concentrations declined, 0.61 at 90 days and 0.27 at 120 days). These data strongly suggest 
that the observed variation in haloperidol concentrations is due to strain effects (a proxy for 
genetic differences between inbred lines).
The effects of haloperidol on VCMs, EPS, and activity
The central aim of this study was to investigate the relationship between genetic background 
and susceptibility to haloperidol-induced VCMs and other EPS phenotypes across 27 inbred 
mouse strains. Figure 2 summarizes nine dependent variables over all strains at baseline and 
after 30, 60, 90, and 120 days of exposure to haloperidol. Five points are noteworthy. First, 
the wide error bars in Figure 2 (even on a square root scale) suggest that, on average, there is 
considerable variation in all phenotypes across strains. Individual strain and time-point data 
for these nine variables indicate that between strain variation was considerably greater than 
within strain variation at most time points (Figure S4). Second, exposure to haloperidol had 
profound average effects. For example, comparing baseline with day 30, there was a 7-fold 
decrease in vertical activity, 263-fold increase in EPS, and 8-fold increase in overt chewing 
movements. Third, the baseline activity measures showed considerable variability across 
strains (consistent with attempts to map genetic loci for open-field activity) 24, 25. The 
average effect of haloperidol was maximal at day 30 or 60. Average values moved toward 
baseline on days 90 and 120 but did not return to baseline suggesting that the behavioral 
effects of haloperidol persist even when plasma concentrations are low (Table 2). Fourth, 
there was little average variability in EPS at baseline and the strong effects of haloperidol 
exposure were still present at day 120. Fifth, perhaps unlike the activity and EPS measures, 
the average effect of haloperidol on the four VCM measures were notably persistent through 
day 120 without a trend toward baseline values.
We next investigated the effects of confounding variables on the core dependent variables. 
We fit 45 regression models with the dependent variable each phenotype at each time point 
(9 phenotypes × 5 time points). The predictors were drug dose, weight at that time point, 
haloperidol concentration at that time point (log10, omitted for time0), and strain. P-values 
for the coefficients for dose, weight, and haloperidol concentration were always > 0.001 
(Bonferroni correction) whereas P-values for the coefficients for strain were 10−8–10−37 (the 
single exception was P=0.01 for strain for EPS at baseline). Thus, strain effects were the 
main determinant of phenotypic variation with no evident covariate effects. Strain effects 
also accounted for considerable proportions of variation (R2 > 0.6 for most activity and 
VCM measures and >0.7 for EPS after day 0).
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The study of 27 inbred mouse strains allowed calculation of heritability for VCMs, EPS, and 
activity measures. We estimated heritability for these phenotypic data in four progressive 
ways. Figure 3a shows heritability estimates at five time points for the nine phenotypes 
(square root transformations of raw data). Strong genetic effects are evident for virtually all 
phenotypes. To isolate the impact of exposure to haloperidol, Figure 3b depicts the 
heritabilities of haloperidol-induced change scores (√timet – √time0). Heritabilities are 
considerably lower but generally > 0.4. Change scores can be unreliable and reflect error 
variance 26, particularly if the variables in the change score calculation are correlated. For 
example, the correlations of time0 with time30 measures were high for the activity (~0.6) and 
VCM measures (~0.5) but near zero for EPS (−0.07). For all correlated measures, the 
heritability of change scores is markedly lower but not for the uncorrelated EPS measure. 
Thus, the estimates in Figure 3b appear to be artifactually low. Figure 3c provides an 
improved estimation of phenotype-level heritability via analysis of change trajectories. The 
heritability of seven phenotypes exceeded 75% (all except center time and stereotopy).
Factor analysis was then applied to the change score trajectories. As shown in Table 1, the 
first two factors had eigenvalues > 1 and together explained 75% of the shared variance 
among the VCM, activity, and EPS trajectories. These factors are roughly consonant with a 
priori expectations, with Factor 1 explaining most of the variance in the locomotor activity 
response trajectories and Factor 2 primarily explaining the orofacial movement response 
trajectories. However, the factor loadings were not completely specific as some items loaded 
onto both factors. The heritabilities were very high for both factors, with strain differences 
explaining 96% of variance in the orofacial movement latent trajectory factor 2, and 86% of 
variance in the locomotor activity latent trajectory factor 1 (Figure 3D). Strain means for 
factors 1 and 2 are depicted in Figure S5.
DISCUSSION
The purpose of this report was to initiate investigation of murine VCMs with the eventual 
goal of improving understanding of the genomics of human TD. If VCMs are a reasonable 
analogue of TD, then it might be possible to accelerate discovery by using MTH (mouse-
then-human) designs whereby mouse genetic mapping resources are used to screen the 
genomic search space to derive high-probability targets whose orthologs can be studied in 
human samples. In this way, the multiple testing burden is paid in a relatively inexpensive 
and experimentally tractable system and precious human samples are used only for the most 
crucial targets.
To achieve this end, we pursued a number of systematic goals. The initial consideration was 
the ability to deliver human-like concentrations of haloperidol in a sustained, consistent, and 
reliable manner as haloperidol exposure is a critical risk factor for TD 14. A literature 
review 27 and pilot experiments (Table S2) demonstrated that implantable pellets yielded 
lower coefficients of variation for haloperidol levels in plasma (20.6%) and brain (11.6%) 
than other methods of drug delivery (>34%). Additional dose-ranging experiments showed 
that dosing mice with implantable pellets at 3.0 mg/kg/day (60 day sustained release) 
reliably yielded human-like plasma concentrations. The data that form the backbone of this 
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report (Figure 1 and Table S3) indicate that implantable pellets yield low coefficients of 
variation in plasma haloperidol concentrations (median 0.19) and nearly always achieved 
human-like plasma concentrations (>10 nM in 98.1% of mice). Note that two months of 
haloperidol exposure is an appreciable fraction of the ~1.5–2 year lifespan of a laboratory 
mouse and thus constitutes chronic exposure.
Second, we demonstrated that haloperidol concentrations are highly variable between inbred 
strains. The observed variability was not influenced by potential confounders such as the 
dose implanted or body mass. Moreover, within- was considerably less than between-strain 
variation leading to heritability estimates for haloperidol concentrations of ~0.7 during the 
times when the drug was being actively released. Future work will attempt to identify the 
genetic determinants of haloperidol concentrations in a genome-wide and unbiased manner.
Third, we developed a battery of tests to assess the observable effects of haloperidol. 
Following careful rater training and calibration, assessment of VCMs in randomly assigned 
tapes by raters blinded to experimental date was reproducible. An immediate observation 
was that exposure to haloperidol yielded marked average changes across multiple domains. 
Four measures of activity in the open field, one measure of EPS, and four measures of 
orofacial movement all exhibited, on average, marked changes following haloperidol 
exposure (Figure 1). These changes did not return to baseline values by the end of the study 
(120 days). Crucially, these measures were independent of haloperidol plasma level and 
other covariates. Strain was again the major predictor of phenotypic variation.
Fourth, we observed that the three domains we assessed – orofacial movements, activity in 
the open field, and EPS – were not discrete constructs but rather loaded onto two factors. 
Analysis of human data from a large randomized clinical trial (CATIE) 28,show a similar 
pattern: subjects with TD by consensus criteria 29 had greater EPS and akathisia (P values < 
0.0001) 30. To investigate this with an approach closer to that in Table 1, we analyzed the 
CATIE baseline data for total Abnormal Involuntary Movement scale (AIMS) score 31, EPS 
measured by the Abbreviated Simpson–Angus Side Effect Scale 32, and the Barnes 
Akathisia Scale 33. Similar to the analyses in Table 1, two principal components accounted 
for 78% of the variance (see Table S5), and the first component had similar loadings: AIMS 
total (0.61), EPS (0.56), and akathisia (0.56). Therefore, the human and mouse data 
converge and suggest that each of these scales is an imprecise but informative assessment of 
a more fundamental latent construct.
Fifth, we estimated heritability for haloperidol-induced effects on VCMs, activity in the 
open field, and EPS. Figure 3 provides the results at successive levels of processing. Given 
that our design was inherently longitudinal, analysis of the response trajectories of 
individual mice is superior to individual time points and, given the inter-relatedness of the 
phenotype domains, analysis of factors from factor analysis of response trajectories is 
superior to trajectory analysis. Thus, we believe heritability estimates in Figure 3D provide 
the best representation of our study and of the phenotypes themselves. The heritability of 
factor 1 was 0.86 and 0.96 for factor 2. To our knowledge, these are the first estimates of 
heritability for VCMs. Variation in behavioral responses to chronic haloperidol exposure is 
predominantly determined by genetic influences. These data strongly support efforts to 
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identify the specific genetic basis of variation in these traits and augment the case for the 
study of genetic influences on human TD.
A major assumption of the mouse-then-human approach is that murine VCMs are an 
adequate model for the human adverse drug reaction TD. Three criteria are generally applied 
to establish the validity of a mouse model of a human phenotype 34. The pun is 
unavoidable: VCMs have face validity for human TD. Key behavioral markers that define 
the predominant type of TD (repetitive and purposeless movements of the mouth and jaw) 
are highly similar to VCMs (purposeless jaw movements in the vertical plane). A board-
certified neurologist (KW) with considerable experience in the diagnosis and treatment of 
TD reviewed tapes of mice with VCMs and also noted the face validity of VCMs for TD. 
The face validity of VCMs is augmented by multiple additional lines of argument 
(summarized in Table S1), and their persistence over large fractions of the mouse lifespan is 
compelling (Figure S1).
Evaluation of the remaining two criteria for VCMs as a valid model of human TD are for 
future studies. Construct validity requires a conceptual analogy to the cause of human TD. 
This criterion is partially fulfilled given the crucial role of typical antipsychotics in the 
etiology of both VCMs and TD. However, fully evaluating this criterion is a fundamental 
goal of the MTH design – if susceptibility loci can be identified in mouse, do the 
orthologous regions in human contain susceptibility loci for TD? The final criterion – 
predictive validity – assesses (in part) specificity of treatment response. Although this could 
be studied in the absence of precise pathophysiology, it is far more interesting to conduct 
such studies with the greater insight afforded by a clear understanding of how genes and 
haloperidol exposure interact to produce VCMs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Haloperidol plasma concentrations (in nM) per strain at four time points
All data points are shown for all strains with a non-linear smoothing function added.
Crowley et al. Page 13













Figure 2. Summary of dependent variables (activity, EPS, and VCMs) over all strains
Each plot shows data for one dependent variable for five time points (baseline and 30, 60, 
90, and 120 days). Shown are means and SEM error bars for over all strains (square root 
transformation).
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Figure 3. Heritability estimates
A) Heritability estimates for each dependent variable (square root transformation) at five 
time points (baseline and 30, 60, 90, and 120 days). B) Heritability estimates of change in 
phenotype from baseline (√timet – √time0). C) Heritability estimates for response trajectories 
of change scores. D) Heritability of factor analysis of response trajectories.
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